Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-L1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.

NCT07348107 is registered in ClinicalTrials.gov with Daniel Breadner as lead sponsor.

NCT NCT07348107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07348107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-L1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
Lead sponsor
Daniel Breadner
Phase
Phase 1
Overall status
Not yet recruiting
Start date
February 15, 2026
Completion date
March 31, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic ductal adenocarcinoma